论文部分内容阅读
目的探讨糖尿病患者糖化血红蛋白水平与血小板膜GPⅡb/Ⅲa复合物纤维蛋白原受体(PAC-1)和P选择素(CD 62P)的关系及其临床意义。方法采用流式细胞仪三色荧光标记技术来测定45例40岁以下初发的2型糖尿病患者及20名健康对照组的PAC-1、CD 62P的表达率和糖化血红蛋白A1(GHbA1)比率,同时进行治疗前后及与对照组比较。结果初发的2型糖尿病组PAC-1(12.38±3.15%)、CD 62P(8.74±2.01%)、GHbA1(9.53±2.73%),其表达分别显著高于健康对照组的2.67±1.52%(P<0.001)、1.07±1.41%(P<0.001)、6.21±1.05%(P<0.001)。降糖治疗6月后糖尿病组血糖达标,PAC-1(7.38±3.25%)、CD 62P(6.26±3.01%)、GHbA1(6.33±1.46%),与治疗前比较有显著差异(P<0.001)。结论2型糖尿病血小板活化与糖化血红蛋白水平密切相关。严格控制血糖可以抑制血小板活化,预防血栓性疾病的发生。
Objective To investigate the relationship between glycated hemoglobin (HbA1c) and platelet membrane glycoprotein receptor (PAC-1) and P-selectin (CD62P) in patients with diabetes and its clinical significance. Methods The expression of PAC-1, CD 62P and the ratio of HbA1 in 45 patients with type 2 diabetes mellitus under 40 years old and 20 healthy controls were determined by flow cytometry with three-color fluorescence labeling. Before and after treatment and compared with the control group. Results The rates of PAC-1, CD 62P (8.74 ± 2.01%) and GHbA1 (9.53 ± 2.73%) in newly diagnosed type 2 diabetic patients were significantly higher than those in healthy controls (2.67 ± 1.52% P <0.001), 1.07 ± 1.41% (P <0.001), 6.21 ± 1.05% (P <0.001). There was significant difference (P <0.001) in blood glucose between the diabetic group and the control group after 6 months of hypoglycemic treatment, with PAC-1 (7.38 ± 3.25%), CD 62P (6.26 ± 3.01%) and GHbA1 (6.33 ± 1.46% . Conclusion Platelet activation in type 2 diabetes is closely related to HbA1c level. Strict control of blood sugar can inhibit platelet activation, prevention of thrombotic diseases.